Tag: pharma policy

Governance Models and Cross-Functional Ownership for Start-Up vs. Big Pharma Operating Models Governance Models and Cross-Functional Ownership for Start-Up vs. Big Pharma Operating Models In the rapidly evolving landscape of clinical trials, the governance structure and operational models adopted by organizations can significantly influence the efficiency and success of their research projects. This tutorial provides…

Read More “Governance Models and Cross-Functional Ownership for Start-Up vs. Big Pharma Operating Models” »

Start-Up vs. Big Pharma Operating Models: What Clinical Leaders Need to Know Now Introduction The world of clinical research is characterized by diverse operational models that are primarily dictated by the scale and scope of the organizations involved. In this detailed tutorial, we will explore the operational differences between start-up organizations and large pharmaceutical companies,…

Read More “Start-Up vs. Big Pharma Operating Models: What Clinical Leaders Need to Know Now” »

How to Model Start-Up vs. Big Pharma Operating Models for Global Study Portfolios How to Model Start-Up vs. Big Pharma Operating Models for Global Study Portfolios In the rapidly evolving landscape of clinical research trials, understanding the operational models between start-ups and big pharmaceutical companies is crucial for the effective management of global study portfolios….

Read More “How to Model Start-Up vs. Big Pharma Operating Models for Global Study Portfolios” »

Start-Up vs. Big Pharma Operating Models in Practice: Benchmarks, Case Studies and Playbooks The clinical research landscape has evolved significantly, presenting distinct operational models that either start-ups or large pharmaceutical companies utilize in the development and execution of clinical trials. This article serves as a comprehensive guide for clinical operations, regulatory affairs, and medical affairs…

Read More “Start-Up vs. Big Pharma Operating Models in Practice: Benchmarks, Case Studies and Playbooks” »

High-Impact Start-Up vs. Big Pharma Operating Models Strategies That Protect Trial Timelines and Margins High-Impact Start-Up vs. Big Pharma Operating Models Strategies That Protect Trial Timelines and Margins Introduction to Clinical Trial Operating Models In the contemporary landscape of clinical research, the operating models of start-ups and large pharmaceutical companies diverge significantly. Understanding these models,…

Read More “High-Impact Start-Up vs. Big Pharma Operating Models Strategies That Protect Trial Timelines and Margins” »

Linking Start-Up vs. Big Pharma Operating Models to Market Access, HTA and Payer Expectations Linking Start-Up vs. Big Pharma Operating Models to Market Access, HTA and Payer Expectations As the landscape of clinical trials evolves, understanding how different operational models impact market access, health technology assessment (HTA), and payer expectations is crucial for both start-ups…

Read More “Linking Start-Up vs. Big Pharma Operating Models to Market Access, HTA and Payer Expectations” »